Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 4/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9197462 | 0.69 | GSK3B (0.47) | GSK3BTNKS2NPC1SMN1; SMN2CYP1A2 | |
| SCHEMBL11914645 | 0.69 | GSK3B (0.47) | GSK3BTNKS2NPC1IDH1SMN1; SMN2 | |
| SCHEMBL12510427 | 0.66 | GSK3B (0.56) | GSK3BTNKS2NPC1SMN1; SMN2CYP1A2 | |
| SCHEMBL19411558 | 0.66 | GSK3B (0.48) | GSK3BTNKS2SMN1; SMN2CYP1A2 | |
| SCHEMBL1104593 | 0.65 | GSK3B (0.33) | GSK3BTNKS2IDH1GAA | |
| SCHEMBL4471060 | 0.65 | MEN1 (0.51) | NPC1SMN1; SMN2GAAKDM4EHSD17B10 | |
| SCHEMBL8645020 | 0.65 | GSK3B (0.43) | GSK3BTNKS2NPC1SMN1; SMN2CYP1A2 | |
| SCHEMBL828557 | 0.64 | IDH1 (0.43) | IDH1 | |
| SCHEMBL14030338 | 0.63 | GSK3B (0.47) | GSK3BTNKS2NPC1IDH1SMN1; SMN2 | |
| SCHEMBL14048223 | 0.63 | GSK3B (0.51) | GSK3BTNKS2NPC1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | GSK3B 259/4885TNKS2 2983/4885NPC1 1334/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | GSK3B 259/4885TNKS2 2983/4885NPC1 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.